Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Inc Share Price USD0.0001
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology
Puma shares nearly triple on drug news, but options smell 'fishy'
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Puma Biotechnology, Inc.
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology falls more than 20%
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology - STAT
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
